JP2020511131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511131A5 JP2020511131A5 JP2019548664A JP2019548664A JP2020511131A5 JP 2020511131 A5 JP2020511131 A5 JP 2020511131A5 JP 2019548664 A JP2019548664 A JP 2019548664A JP 2019548664 A JP2019548664 A JP 2019548664A JP 2020511131 A5 JP2020511131 A5 JP 2020511131A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- population
- cell according
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022104262A JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2023204311A JP7608580B2 (ja) | 2017-03-08 | 2023-12-04 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2024221238A JP7806197B2 (ja) | 2017-03-08 | 2024-12-18 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2026004149A JP2026063125A (ja) | 2017-03-08 | 2026-01-14 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762468890P | 2017-03-08 | 2017-03-08 | |
| US62/468,890 | 2017-03-08 | ||
| PCT/US2018/021332 WO2018165291A1 (en) | 2017-03-08 | 2018-03-07 | MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104262A Division JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511131A JP2020511131A (ja) | 2020-04-16 |
| JP2020511131A5 true JP2020511131A5 (https=) | 2021-04-08 |
| JP7098648B2 JP7098648B2 (ja) | 2022-07-11 |
Family
ID=63446373
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548664A Active JP7098648B2 (ja) | 2017-03-08 | 2018-03-07 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2022104262A Active JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2023204311A Active JP7608580B2 (ja) | 2017-03-08 | 2023-12-04 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2024221238A Active JP7806197B2 (ja) | 2017-03-08 | 2024-12-18 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2026004149A Pending JP2026063125A (ja) | 2017-03-08 | 2026-01-14 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104262A Active JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2023204311A Active JP7608580B2 (ja) | 2017-03-08 | 2023-12-04 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2024221238A Active JP7806197B2 (ja) | 2017-03-08 | 2024-12-18 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2026004149A Pending JP2026063125A (ja) | 2017-03-08 | 2026-01-14 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US10801013B2 (https=) |
| EP (1) | EP3592845A4 (https=) |
| JP (5) | JP7098648B2 (https=) |
| KR (4) | KR102626748B1 (https=) |
| CN (2) | CN116440293A (https=) |
| AU (2) | AU2018231193B2 (https=) |
| CA (1) | CA3053252C (https=) |
| IL (3) | IL326426A (https=) |
| WO (1) | WO2018165291A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10801013B2 (en) | 2017-03-08 | 2020-10-13 | Nantkwest, Inc. | Modified NK-92 haNK003 cells for the clinic |
| JP7241161B2 (ja) | 2018-08-01 | 2023-03-16 | イミュニティーバイオ、インコーポレイテッド | 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム |
| EP3743512A4 (en) | 2018-10-31 | 2021-12-01 | Nantkwest, Inc. | ELIMINATION OF CD19 POSITIVE LYMPHOID MALIGNITIES BY CD19 CAR EXPRESSING NK CELLS |
| CN113164521A (zh) * | 2018-11-26 | 2021-07-23 | 免疫生物公司 | 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞 |
| EP3938495A4 (en) | 2019-03-15 | 2023-04-26 | Nantcell, Inc. | RECOMBINANT ERIL-15 NK CELLS |
| CA3148608A1 (en) * | 2019-07-26 | 2021-02-04 | Immunitybio, Inc. | Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis |
| AU2020387167B2 (en) * | 2019-11-20 | 2024-10-24 | Immunitybio, Inc. | Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment |
| CN113646435A (zh) * | 2019-12-09 | 2021-11-12 | 南克维斯特公司 | 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆 |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| KR20230152783A (ko) | 2020-07-07 | 2023-11-03 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| EP4232567A1 (en) * | 2020-10-26 | 2023-08-30 | Shoreline Biosciences, Inc. | Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells |
| CN114807237A (zh) * | 2022-05-12 | 2022-07-29 | 广东普罗凯融生物医药科技有限公司 | 一种过表达CD16a的NK细胞的制备方法及其应用 |
| EP4548096A1 (en) * | 2022-06-28 | 2025-05-07 | Cellply S.R.L. | Method for the characterization of products for cell therapy |
| US20250298030A1 (en) * | 2024-03-20 | 2025-09-25 | Immunitybio, Inc. | Compositions and Methods for NK-92 Cells Expressing Native CD16 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11510698A (ja) * | 1995-08-04 | 1999-09-21 | ザ ジェネラル ホスピタル コーポレイション | トランスジェニックブタ及びヒトｈｌａ遺伝子を有するブタ細胞 |
| TW555562B (en) * | 1996-12-27 | 2003-10-01 | Kirin Brewery | Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof |
| CA2289915A1 (en) * | 1997-04-30 | 1998-11-05 | Hans Klingemann | Natural killer cell lines and methods of use |
| ATE323756T1 (de) | 1997-04-30 | 2006-05-15 | Hans Klingemann | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
| US8034332B2 (en) | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
| AU2005277831B2 (en) * | 2004-07-10 | 2012-11-22 | The Institute For Cancer Research | Genetically modified human natural killer cell lines |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| CN117379460A (zh) * | 2015-03-27 | 2024-01-12 | 免疫生物公司 | 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 |
| EP3307876B1 (en) | 2015-06-10 | 2023-09-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| US10801013B2 (en) | 2017-03-08 | 2020-10-13 | Nantkwest, Inc. | Modified NK-92 haNK003 cells for the clinic |
-
2018
- 2018-03-07 US US15/914,665 patent/US10801013B2/en active Active
- 2018-03-07 KR KR1020237015931A patent/KR102626748B1/ko active Active
- 2018-03-07 IL IL326426A patent/IL326426A/en unknown
- 2018-03-07 CA CA3053252A patent/CA3053252C/en active Active
- 2018-03-07 KR KR1020247001475A patent/KR102769529B1/ko active Active
- 2018-03-07 IL IL268617A patent/IL268617B2/en unknown
- 2018-03-07 AU AU2018231193A patent/AU2018231193B2/en active Active
- 2018-03-07 JP JP2019548664A patent/JP7098648B2/ja active Active
- 2018-03-07 KR KR1020257004694A patent/KR20250026391A/ko active Pending
- 2018-03-07 KR KR1020197028804A patent/KR102533061B1/ko active Active
- 2018-03-07 EP EP18763512.3A patent/EP3592845A4/en active Pending
- 2018-03-07 WO PCT/US2018/021332 patent/WO2018165291A1/en not_active Ceased
- 2018-03-07 CN CN202310355496.3A patent/CN116440293A/zh active Pending
- 2018-03-07 CN CN201880016940.6A patent/CN110418839B/zh active Active
-
2019
- 2019-05-28 US US16/424,201 patent/US10774310B2/en active Active
-
2020
- 2020-07-23 US US16/937,370 patent/US11753625B2/en active Active
-
2021
- 2021-09-23 AU AU2021236511A patent/AU2021236511B2/en active Active
-
2022
- 2022-06-29 JP JP2022104262A patent/JP7398518B2/ja active Active
-
2023
- 2023-07-18 US US18/223,338 patent/US12492377B2/en active Active
- 2023-12-04 JP JP2023204311A patent/JP7608580B2/ja active Active
-
2024
- 2024-10-08 IL IL316209A patent/IL316209B1/en unknown
- 2024-12-18 JP JP2024221238A patent/JP7806197B2/ja active Active
-
2025
- 2025-11-10 US US19/385,045 patent/US20260078342A1/en active Pending
-
2026
- 2026-01-14 JP JP2026004149A patent/JP2026063125A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511131A5 (https=) | ||
| CN115651927A (zh) | 编辑rna的方法和组合物 | |
| CN113518821A (zh) | 用于免疫疗法的经修饰的自然杀伤(nk)细胞 | |
| US12319740B2 (en) | Methods for production of tissue resident memory-like T cells and use thereof | |
| CN118389602B (zh) | 经人工操纵的免疫细胞 | |
| CN105120879A (zh) | 干细胞微粒及miRNA | |
| CN104703609A (zh) | 干细胞微粒 | |
| CN105142646A (zh) | 产生微粒的方法 | |
| EP3534921A1 (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| CN105658789A (zh) | 干细胞微粒和miRNA | |
| CN104321062A (zh) | 干细胞微粒 | |
| CN108026526A (zh) | 用于改善移植的crispr/cas相关方法和组合物 | |
| JP2016514953A (ja) | テロメア伸長に関する化合物、組成物、方法及びキット | |
| WO2007099534A3 (en) | Compostions and populations of cells obtained from the umbilical cord and methods of producing the same | |
| TWI900630B (zh) | 用於富集基因改造t細胞之方法 | |
| JP2024512608A5 (https=) | ||
| ATE482720T1 (de) | Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen | |
| EP4423280A1 (en) | Method for repairing hair cycle-related genes and method for treating hair cycle-related diseases using mir-520d-5p | |
| IL138615A0 (en) | Alphaviral gene expression system and dna molecules for use therein | |
| Xiao et al. | Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity | |
| Robert et al. | Expression of an interleukin-2 partial agonist enhances regulatory T cell persistence and efficacy in mouse autoimmune models | |
| CN119836571A (zh) | 用于调节遗传驱动因子的组合物和方法 | |
| JP2020517289A5 (https=) | ||
| EP3521428A1 (en) | PROMOTER OF Hspa5 GENE | |
| Hu et al. | Artificial Cell-Derived Vesicles: Extracellular Vesicle Mimetics for Chondrocyte Restoration in TMJOA Therapy |